IND Acceptance

News

The puzzle of Alzheimer's, HCP hand holds digital graphic of brain and missing puzzle piece

Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2

Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.

News

argenx's Forte acquisition delivers coeliac trial win

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks